Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Shares Bought by Marshall Wace LLP

Marshall Wace LLP grew its holdings in shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT) by 1,196.3% during the second quarter, according to its most recent Form 13F filing with the SEC. The firm owned 43,335 shares of the biotechnology company’s stock after purchasing an additional 39,992 shares during the period. Marshall Wace LLP’s holdings in Sarepta Therapeutics were worth $6,847,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also modified their holdings of the stock. Vanguard Group Inc. raised its position in shares of Sarepta Therapeutics by 2.8% during the 4th quarter. Vanguard Group Inc. now owns 8,816,124 shares of the biotechnology company’s stock worth $850,139,000 after buying an additional 243,180 shares in the last quarter. Capital International Investors increased its stake in shares of Sarepta Therapeutics by 1.6% during the first quarter. Capital International Investors now owns 4,817,517 shares of the biotechnology company’s stock valued at $623,676,000 after acquiring an additional 76,032 shares during the period. Avoro Capital Advisors LLC raised its holdings in Sarepta Therapeutics by 7.9% during the fourth quarter. Avoro Capital Advisors LLC now owns 4,344,444 shares of the biotechnology company’s stock worth $418,935,000 after purchasing an additional 319,444 shares in the last quarter. Wellington Management Group LLP lifted its position in Sarepta Therapeutics by 5.6% in the fourth quarter. Wellington Management Group LLP now owns 4,127,610 shares of the biotechnology company’s stock worth $398,025,000 after purchasing an additional 217,810 shares during the period. Finally, Farallon Capital Management LLC boosted its stake in Sarepta Therapeutics by 102.8% during the 1st quarter. Farallon Capital Management LLC now owns 2,453,500 shares of the biotechnology company’s stock valued at $317,630,000 after purchasing an additional 1,243,427 shares in the last quarter. 86.68% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

Several research analysts recently weighed in on SRPT shares. Needham & Company LLC reaffirmed a “buy” rating and set a $235.00 target price on shares of Sarepta Therapeutics in a research note on Thursday, June 27th. William Blair upgraded shares of Sarepta Therapeutics to a “strong-buy” rating in a report on Friday, August 30th. UBS Group raised their target price on shares of Sarepta Therapeutics from $173.00 to $188.00 and gave the stock a “buy” rating in a report on Tuesday, September 17th. Robert W. Baird upped their price target on Sarepta Therapeutics from $170.00 to $200.00 and gave the company an “outperform” rating in a report on Friday, June 21st. Finally, Morgan Stanley reissued an “overweight” rating and set a $165.00 price objective on shares of Sarepta Therapeutics in a research note on Friday, June 21st. Three research analysts have rated the stock with a hold rating, sixteen have issued a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, Sarepta Therapeutics currently has an average rating of “Moderate Buy” and an average target price of $187.39.

Sarepta Therapeutics Trading Up 0.3 %

NASDAQ SRPT opened at $124.89 on Tuesday. The company has a current ratio of 3.90, a quick ratio of 3.19 and a debt-to-equity ratio of 1.05. Sarepta Therapeutics, Inc. has a 1-year low of $55.25 and a 1-year high of $173.25. The firm’s fifty day simple moving average is $134.56 and its 200-day simple moving average is $132.86. The company has a market capitalization of $11.81 billion, a PE ratio of 1,135.36 and a beta of 0.81.

Sarepta Therapeutics (NASDAQ:SRPT) last issued its earnings results on Wednesday, August 7th. The biotechnology company reported $0.07 earnings per share for the quarter, topping the consensus estimate of $0.01 by $0.06. The company had revenue of $362.90 million for the quarter, compared to analyst estimates of $394.38 million. Sarepta Therapeutics had a return on equity of 5.32% and a net margin of 3.14%. The business’s revenue was up 38.9% compared to the same quarter last year. During the same period in the prior year, the firm posted ($0.27) EPS. As a group, sell-side analysts anticipate that Sarepta Therapeutics, Inc. will post 1.45 earnings per share for the current fiscal year.

Insider Activity at Sarepta Therapeutics

In other news, CFO Ian Michael Estepan sold 5,985 shares of the stock in a transaction on Friday, August 30th. The shares were sold at an average price of $137.36, for a total transaction of $822,099.60. Following the transaction, the chief financial officer now owns 33,946 shares in the company, valued at approximately $4,662,822.56. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. In related news, Director Michael Andrew Chambers purchased 37,038 shares of Sarepta Therapeutics stock in a transaction on Friday, August 16th. The stock was bought at an average price of $133.80 per share, with a total value of $4,955,684.40. Following the completion of the transaction, the director now directly owns 284,034 shares of the company’s stock, valued at $38,003,749.20. The acquisition was disclosed in a filing with the SEC, which can be accessed through this link. Also, CFO Ian Michael Estepan sold 5,985 shares of the company’s stock in a transaction dated Friday, August 30th. The stock was sold at an average price of $137.36, for a total value of $822,099.60. Following the sale, the chief financial officer now owns 33,946 shares of the company’s stock, valued at approximately $4,662,822.56. The disclosure for this sale can be found here. Insiders own 7.70% of the company’s stock.

About Sarepta Therapeutics

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.